Thank you very much, Mr. Chair.
I want to thank all the witnesses but also my colleagues around the table for allowing us to look at this, because I think that at the end of the day the purpose of this was to compensate people who were horribly damaged by this drug.
I want to talk to Health Canada first.
I understand you did your research and helped design and regulate the requirements for eligibility, the criteria for the compensation package. My understanding is that in its report in 2014, the WHO's meeting of experts on thalidomide embryopathy recommended that genetic testing and clinical genetic evaluations be done to help diagnose thalidomide embryopathy where possible.
I know the timeline. That was in 2014. You were well into your work. Did you take those recommendations into account when you were coming up with the criteria that you gave to Crawford?